DRW is dedicated to tackling some of the world’s most serious infectious diseases using breakthrough point of care (POC) diagnostics.
Our SAMBA platforms offer rapid and reliable testing in real-world settings, enabling effective disease management in the most challenging, remote and resource-limited settings.
Bringing infectious disease testing to the patient - We understand the operational needs and obstacles working at the point of care. The SAMBA platforms are the simplest and most robust molecular diagnostic systems available, with both instruments operating across a broad temperature range. With SAMBA there is no need for air conditioning, cold chain transport and storage or highly-trained operators.
Flexible instrument system for diagnosis and therapy monitoring - The SAMBA I system is capable of processing up to six samples simultaneously, with a throughput of up to 72 samples/day – ideal for district or regional hospitals.
SAMBA II: A real game changer in infectious disease management
Fully automated sample in, result out – true Point of Care diagnostics for the most demanding conditions. This easy-to-use instrument offers an all-in-one process from sample extraction, through nucleic acid amplification, detection and interpretation of results.
... so we left rather successful careers and came to Cambridge University in order to bring high-tech to resource limited settings at the end of a dirt road.
Dr. Helen Lee, Chairman and CEO, DRW
DRW was established nearly two decades ago by a group of senior industry scientists. Our unwavering mission is to develop innovative, cost-effective, high-performance and simple to use point of care diagnostics that can perfectly handle the harsh conditions of resource-limited settings in both developed and developing countries.
DRW has two R&D and manufacturing sites, both ISO 13485:2016 certified.